# Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

> **NCT06376396** · PHASE4 · NOT_YET_RECRUITING · sponsor: **R-Evolution Worldwide S.r.l. Impresa Sociale** · enrollment: 300 (estimated)

## Conditions studied

- Neurocysticercosis

## Interventions

- **DRUG:** albendazole and praziquantel
- **DRUG:** Albendazole

## Key facts

- **NCT ID:** NCT06376396
- **Lead sponsor:** R-Evolution Worldwide S.r.l. Impresa Sociale
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376396, "Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06376396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*